Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

Bart Keymeulen, Sophie Candon, Samira Fafi-Kremer, Anette Ziegler, Marianne Leruez-Ville, Chantal Mathieu, Evy Vandemeulebroucke, Markus Walter, Laurent Crenier, Eric Thervet, Christophe Legendre, Denis Pierard, Geoff Hale, Herman Waldmann, Jean-François Bach, Jean Marie Seigneurin, Daniel Pipeleers, Lucienne Chatenoud

Blood (2010) 115 (6): 1145–1155.

https://doi.org/10.1182/blood-2009-02-204875

Published: 2010

Includes: Supplemental data

Journal Articles

Myeloablative Conditioning Is Well Tolerated by Older Patients Receiving T-Cell Depleted Grafts.

Nicolas Novitzky, MD, PhD, Valda Thomas, Geoff Hale, Herman Waldmann

Blood (2005) 106 (11): 5266.

https://doi.org/10.1182/blood.V106.11.5266.5266

Published: 2005

Journal Articles

Radiotherapy-Based Conditioning Is Effective Immunosuppression for Patients Undergoing Transplantation with T-Cell Depleted Stem Cell Grafts for Severe Aplasia.

Nicolas Novitzky, MD, PhD, Valda Thomas, Helen Stubbings, Geoff Hale, Herman Waldmann

Blood (2004) 104 (11): 1819.

https://doi.org/10.1182/blood.V104.11.1819.1819

Published: 2004

Journal Articles

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Geoff Hale, Peppy Rebello, Lee R. Brettman, Chris Fegan, Ben Kennedy, Eva Kimby, Mike Leach, Jeanette Lundin, Håkan Mellstedt, Paul Moreton, Andy C. Rawstron, Herman Waldmann, Anders Osterborg, Peter Hillmen

Blood (2004) 104 (4): 948–955.

https://doi.org/10.1182/blood-2004-02-0593

Published: 2004

Journal Articles

Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation

Suparno Chakrabarti, Donald W. Milligan, Deenan Pillay, Stephen Mackinnon, Kathleen Holder, Narinder Kaur, Dorothy McDonald, Christopher D. Fegan, Herman Waldmann, Geoff Hale, Alan Rickinson, Neil Steven

Blood (2003) 102 (3): 839–842.

https://doi.org/10.1182/blood.V102.3.839

Published: 2003

Journal Articles

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm, Per-Anders Broliden, Fredrik Celsing, Viktoria Hjalmar, Lars Möllgård, Peppy Rebello, Geoff Hale, Herman Waldmann, Håkan Mellstedt, Anders Österborg

Blood (2002) 100 (3): 768–773.

https://doi.org/10.1182/blood-2002-01-0159

Published: 2002

Journal Articles

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

Suparno Chakrabarti, Stephen Mackinnon, Raj Chopra, Panagiotis D. Kottaridis, Karl Peggs, Peter O'Gorman, Ronjon Chakraverty, Timothy Marshall, Husam Osman, Premini Mahendra, Charles Craddock, Herman Waldmann, Geoff Hale, Christopher D. Fegan, Kwee Yong, Anthony H. Goldstone, David C. Linch, Donald W. Milligan

Blood (2002) 99 (12): 4357–4363.

https://doi.org/10.1182/blood.V99.12.4357

Published: 2002

Journal Articles

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Blood (2002) 99 (3): 1071–1078.

https://doi.org/10.1182/blood.V99.3.1071

Published: 2002

Journal Articles

Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions

Patricia A. Taylor, Christopher J. Lees, Herman Waldmann, Randolph J. Noelle, Bruce R. Blazar

Blood (2001) 98 (2): 467–474.

https://doi.org/10.1182/blood.V98.2.467

Published: 2001

Journal Articles

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

Blood (2000) 96 (7): 2419–2425.

https://doi.org/10.1182/blood.V96.7.2419

Published: 2000

Journal Articles

Children With Acute Lymphoblastic Leukemia Who Receive T-Cell–Depleted HLA Mismatched Marrow Allografts From Unrelated Donors Have an Increased Incidence of Primary Graft Failure but a Similar Overall Transplant Outcome

Ann Green, Emer Clarke, Linda Hunt, Andrew Canterbury, Alan Lankester, Geoff Hale, Herman Waldmann, Sally Goodman, Jacqueline M. Cornish, David I. Marks, Colin G. Steward, Anthony Oakhill, Derwood H. Pamphilon

Blood (1999) 94 (7): 2236–2246.

https://doi.org/10.1182/blood.V94.7.2236.419k04_2236_2246

Published: 1999

Journal Articles

Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection

Geoff Hale, Mei-Jie Zhang, Donald Bunjes, H. Grant Prentice, David Spence, Mary M. Horowitz, A. John Barrett, Herman Waldmann

Blood (1998) 92 (12): 4581–4590.

https://doi.org/10.1182/blood.V92.12.4581

Published: 1998

Journal Articles

Risks of Developing Epstein-Barr Virus–Related Lymphoproliferative Disorders After T-Cell–Depleted Marrow Transplants

Geoff Hale, Herman Waldmann, CAMPATH Users

Blood (1998) 91 (8): 3079–3083.

https://doi.org/10.1182/blood.V91.8.3079.3079_3079_3083

Published: 1998

Journal Articles

Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I α1 Domain

Laurent Genestier, Romain Paillot, Nathalie Bonnefoy-Berard, Geneviéve Meffre, Monique Flacher, David Fèvre, Yong Jun Liu, Philippe Le Bouteiller, Herman Waldmann, Victor H. Engelhard, Jacques Banchereau, Jean Pierre Revillard

Blood (1997) 90 (9): 3629–3639.

https://doi.org/10.1182/blood.V90.9.3629

Published: 1997

NARROW

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

Myeloablative Conditioning Is Well Tolerated by Older Patients Receiving T-Cell Depleted Grafts.

Radiotherapy-Based Conditioning Is Effective Immunosuppression for Patients Undergoing Transplantation with T-Cell Depleted Stem Cell Grafts for Severe Aplasia.

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

Children With Acute Lymphoblastic Leukemia Who Receive T-Cell–Depleted HLA Mismatched Marrow Allografts From Unrelated Donors Have an Increased Incidence of Primary Graft Failure but a Similar Overall Transplant Outcome

Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection

Risks of Developing Epstein-Barr Virus–Related Lymphoproliferative Disorders After T-Cell–Depleted Marrow Transplants

Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I α1 Domain

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only